0000358654
Donate
Go back to the list of active substances

6-mercaptopurine monohydrate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

6-mercaptopurine monohydrate is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01BB
L01BB Purine analogues
EMA approval status :
Approved
EMA approval date :
2012-03-09
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No